Alnylam-Aktie vor starkem Quartal - Amvuttra-Einführung an Fahrt gewinnt: 13.06. Alnylam stock poised for strong quarter as Amvuttra launch gains traction: Firmen im Artikel. 5-Tage-Chart ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy. − First and Only RNAi Therapeutic Approved by the European ...

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration approval of the supplemental New Drug Application for its RNAi ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran). Portfolio of Marketed Drugs Boosts Revenues ...

Alnylam plans to file for FDA approval of Amvuttra in ATTR-CM later this year and will use a priority review voucher, which will slice by four months the regulator’s standard 10-month appraisal ...

Investing.com - BMO Capital raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) stock to $360 from its previous target while maintaining an Outperform rating.

Alnylam Pharmaceuticals (NasdaqGS:ALNY) recently announced the appointment of Dr. Pushkal Garg as Executive Vice President and Chief Research and Development Officer to accelerate its R&D efforts.

Chardan keeps $325 price target on Alnylam, citing strong Amvuttra launch potential Most of Alnylam’s manufacturing and IP is U.S.-based, easing tariff concerns See how Matt Maley is positioning ...

Alnylam currently markets four drugs — Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran). Portfolio of Marketed Drugs Boosts Revenues ...

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR ...